The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in $20% of non-small cell lung cancers (NSCLC). LKB1 is the major upstream kinase activating the energy-sensing kinase AMPK, making LKB1-deficient cells unable to appropriately sense metabolic stress. We tested the therapeutic potential of metabolic drugs in NSCLC and identified phenformin, a mitochondrial inhibitor and analog of the diabetes therapeutic metformin, as selectively inducing apoptosis in LKB1-deficient NSCLC cells. Therapeutic trials in Kras-dependent mouse models of NSCLC revealed that tumors with Kras and Lkb1 mutations, but not those with Kras and p53 mutations, showed selective response to phenformin as a single agent, resulting in prolonged survival. This study suggests phenformin as a cancer metabolism-based therapeutic to selectively target LKB1-deficient tumors.
INTRODUCTION
The gene encoding the serine/threonine kinase LKB1 was identified originally as the tumor suppressor gene responsible for the inherited cancer disorder Peutz-Jeghers syndrome (Hemminki et al., 1998) . LKB1 is also the second most commonly mutated tumor suppressor in sporadic human lung cancer (after TP53), particularly in multiple subtypes of NSCLC (Sanchez-Cespedes et al., 2002) . LKB1 is mutated in at least 15%-30% of NSCLCs, but the true frequency might be even higher because of difficulties in detecting inactivating lesions (Ding et al., 2008; Gill et al., 2011; Ji et al., 2007) . Roughly half of the NSCLC tumors with LKB1 mutation also bear activating KRAS mutations, and current estimates suggest that 7%-10% of all NSCLC are comutated for KRAS and LKB1 (Ding et al., 2008 ; The Cancer Genome Atlas). Studies in genetically engineered mouse models have shown that simultaneous activation of Kras G12D and biallelic deletion of Lkb1 in the lung dramatically increases tumor burden and metastasis (Carretero et al., 2010; Chen et al., 2012; Ji et al., 2007) .
Biochemical and genetic analyses in worms, flies, and mice have shown that LKB1 is the major kinase phosphorylating the AMP-activated protein kinase (AMPK) under conditions of energy stress across metazoans (Hardie et al., 2012) . AMPK is a highly conserved energy sensor and modulator of cell growth and metabolism that is activated under conditions of low intracellular ATP. Activated AMPK regulates cell growth at least in
Significance
Targeted therapeutics are making significant advances in subsets of NSCLC bearing activated oncogenic targets, such as EGFR and ALK. More prevalent in NSCLC are mutations in the KRAS oncogene coincident with mutations in the LKB1 or p53 tumor suppressor genes. Currently, there are limited options for LKB1 mutant tumors. Here, we define the hypersensitivity of LKB1-defective cells to metabolic stress and test the therapeutic use of phenformin, a mitochondrial inhibitor and a former type 2 diabetes drug, in mouse models of NSCLC. Phenformin as a single agent reduced tumor burden and prolonged survival in Kras;Lkb1 compound mutant mice but not Kras;p53 mice. These findings suggest phenformin or related agents may find clinical utility to treat NSCLC bearing LKB1 mutations. 
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Phenformin Therapy Targets LKB1-Deficient NSCLC part through inhibition of mTORC1 signaling achieved through dual phosphorylation of TSC2 (Inoki et al., 2003) and Raptor (Gwinn et al., 2008) . AMPK is also hypothesized to maintain energy homeostasis in part by targeting defective mitochondria for autophagy (Egan et al., 2011) and control of fatty acid metabolism (Jeon et al., 2012) . The diabetes therapeutic biguanide compounds metformin and phenformin have been shown to inhibit complex I of the mitochondria (Dykens et al., 2008; El-Mir et al., 2000; Owen et al., 2000) , resulting in increases in intracellular AMP and ADP that bind to the gamma regulatory subunit of AMPK and trigger LKB1-dependent phosphorylation of AMPK (Hawley et al., 2010) . Consistent with activation of a low energy checkpoint, metformin treatment has been found to reduce tumor growth in xenograft, transgenic, and carcinogen-induced mouse cancer models (Algire et al., 2011; Anisimov et al., 2005; Buzzai et al., 2007; Memmott et al., 2010) . Epidemiological studies revealed that diabetic patients taking metformin show a statistically significant reduced tumor incidence (Dowling et al., 2012; Evans et al., 2005) . Given the extensive knowledge on the safety and use of metformin, there is increasing interest in using metformin as an anticancer agent (Taubes, 2012) . Phenformin is a 50-fold more potent inhibitor of mitochondrial complex I than metformin (Dykens et al., 2008; Owen et al., 2000) . Moreover, uptake of metformin, but not phenformin, into tissue appears to require the expression of Organic Cation Transporter 1 (OCT1), which is highly expressed in hepatocytes but not elsewhere (Shu et al., 2007) . Consistent with greater potency and broader tissue bioavailability, phenformin delayed tumor progression in a Pten +/À spontaneous lymphoma mouse model to a much greater extent than metformin (Huang et al., 2008) . In most settings metabolic stress induces a cytostatic growth arrest, dependent in part on AMPK. However, in cells lacking a functional LKB1 pathway, metabolic stress has been demonstrated to result in rapid apoptosis as the cells are unable to sense the energy stress and activate mechanisms to restore energy homeostasis (Shaw et al., 2004) . Similar effects are seen in autophagy-defective cells that are unable to restore metabolism under low nutrient conditions (Jin et al., 2007) . Here, we directly examine the hypothesis that LKB1-deficient lung tumors may be targeted with metabolic drugs.
RESULTS

Phenformin Selectively Induces Apoptosis in LKB1-Deficient NSCLC Cell Lines
We previously reported that nontransformed murine embryonic fibroblasts and HeLa cervical carcinoma cells deficient of LKB1 exhibit increased apoptosis in response to metabolic stresses, including glucose deprivation and the AMP mimetic AICAR (Shaw et al., 2004) . However, whether tumor cells undergo growth arrest or apoptosis following a particular cellular insult is dependent in part on the full constellation of oncogenic mutations present in the cell. We sought to determine whether NSCLC cell lines bearing KRAS mutations and lacking LKB1 would show enhanced rates of apoptosis following metabolic stress treatments compared to isogenic lines in which wildtype LKB1 had been restored.
We performed our initial studies using the KRAS mutant and LKB1-deficient NSCLC cell line A549 and derivatives with retrovirally introduced stable expression of wild-type LKB1 cDNA (LKB1 WT ), a kinase-inactive LKB1 cDNA (LKB1 KD ), or an empty vector (pBABE). These cells were treated with a variety of drugs with established roles in causing metabolic stress: metformin, phenformin, the cell permeable AMP-mimetic AICAR, the glycolysis inhibitor 2-deoxyglucose, or the thiazolidinedione compound troglitazone that acts as a mitochondrial inhibitor in addition to effects on PPARg (Hardie et al., 2012) . Immunoblotting for cleaved caspase 3 and cleaved PARP as markers of apoptosis induction, we observed that, of the agents tested, only phenformin induced apoptosis in the cells lacking functional LKB1 ( Figure 1A ). Although both biguanides lowered ATP production in A549 cells ( Figure S1A available online), phenformin reduced cellular ATP more, consistent with previous studies (Owen et al., 2000; Dykens et al., 2008) . The ATP-lowering effect of both drugs was modestly blunted when wild-type LKB1 was present, consistent with the current model that AMPK acts to restore ATP levels and with previous findings in wild-type and Lkb1-deficient myocytes (Sakamoto et al., 2005) . Consistent with a greater impact on ATP levels, phenformin but not metformin induced apoptosis in A549 cells lacking functional LKB1 by multiple measures: cleaved PARP and caspase 3 immunoblot ( Figure 1B ), activated caspase 3/7 luminescence assay (Figure S1B) , and flow cytometry measuring AnnexinV and 7AAD staining ( Figure 1C ).
As human daily doses of metformin routinely run between 500 and 1,000 mg, and phenformin was given in the range of 50 to 100 mg previously when used clinically, we performed a direct comparison of metformin to phenformin at ratios of 1:1 and 10:1 in time course experiments in isogenic A549 cell lines. At early time points (8 or 12 hr) metformin at 2 or 20 mM or phenformin at 2 mM similarly induced AMPK signaling as shown by increased P-AMPK and P-Raptor levels ( Figure S1C ). However, only phenformin induced higher levels of cellular stress, triggering induction of P-Ser51 eIF2a and its downstream target CHOP, and markers of apoptosis at later times (Figures 1B and See also Figure S1 . S1C). eIF2a phosphorylation and upregulation of CHOP is observed in response to a diverse set of cellular stresses, including the unfolded protein response, nutrient deprivation, and mitochondrial stress (Muaddi et al., 2010; Ye et al., 2010; Chae et al., 2012) . This suggests that although AMPK activation is a rapid and sensitive sensor of ATP loss, its signal plateaus and does not continue to increase with greater ATP loss, when additional stress sensing pathways like eIF2a kinases may be engaged. Note that LKB1 did not impact P-eIF2a or CHOP levels ( Figures 1B and S1C ), indicating that eIF2a signaling is behaving here as an AMPK-independent pathway. To examine how widely the sensitivity of cell lines to apoptosis by phenformin treatment is dictated by LKB1, we tested a panel of NSCLC lines that all had KRAS and LKB1 mutations, but each contained additional unique mutations. Isogenic derivatives of each cell line expressing wild-type or kinase-dead LKB1 were established and examined for sensitivity to phenformin or metformin. Despite each cell line containing different additional mutations, their sensitivity to undergo apoptosis following phenformin treatment was dictated by the LKB1 genotype in all cases ( Figures 1D and S1B ). Protection from phenformin-induced apoptosis was also observed with LKB1-reconstituted NSCLC and cervical cell lines H838 and HeLa, respectively, that are deficient for LKB1 but wild-type for KRAS ( Figure S1B ). Taken altogether, these data indicate that LKB1 dictates the sensitivity of a variety of cancer cell lines to phenformin-induced metabolic catastrophe regardless of the other tumor mutations present.
Developing Genetically Engineered Mouse Models of NSCLC that Can Be Monitored by Bioluminescence Longitudinally Though a handful of studies have begun examining metabolic drugs in xenograft models, of particular concern is that subcutaneous placing a mass of tumor cells into an nonvascularized environment and without appropriate basement membrane attachment will itself result in severe metabolic stress and AMPK activation (Jeon et al., 2012; Laderoute et al., 2006) , thus altering the very pathways being tested here for their impact on therapeutic outcome. To better model LKB1-deficient tumors, we took advantage of the well-characterized adenoviral cre-induced NSCLC models initiated by a conditionally activated K-ras oncogene (Lox-Stop-Lox-Kras G12D , hereafter called Kras), combined with mice bearing floxed alleles of p53 or Lkb1 (Farago et al., 2012) . As previously reported (Chen et al., 2012; Ji et al., 2007) , when p53 deficiency or Lkb1 deficiency is combined with Kras activation, there is a dramatic increase in tumor burden leading to metastasis and earlier death,10-12 weeks post-cre administration in both (Safran et al., 2003) to
Luc (KP luc ) mice. We bred these genotypes into the FVB background whose white coat allowed for noninvasive bioluminescent luciferase imaging without fur removal ( Figures S2A-S2C ).
On the FVB genetic background, KL luc and KP luc mice exhibited comparable extents of tumor burden and similar latency.
We demonstrated that the bioluminesence output from the ROSA26-encoded luciferase was proportional to tumor burden (see the Supplemental Experimental Procedures). Analyzing lung tumor progression in K luc , KL luc , and KP luc mice, we detected bioluminescence as early as 4 weeks in KL luc and KP luc mice and confirmed the presence of adenomas by hematoxylin and eosin (H&E) staining (Figures 2A-2D ; Figures S2A-S2C ). At 6 weeks, tumors in the KL luc and KP luc mice began to change from adenomatous features to a more malignant tumor phenotype typical of carcinomas ( Figure 2D ). The most common histologic pattern in both KL luc and KP luc mice were high-grade invasive papillary adenocarcinoma. Squamous cell and adenosquamous carcinoma were commonly observed tumor subtypes in KL luc mice, as previously noted (Ji et al., 2007) . Interestingly, KL luc mice also displayed severe mucinous bronchiolar-epithelial adenocarcinoma (mBEAC) and bronchial mucinous papillary lesions, which were rarely seen in K luc or KP luc mice ( Figure S2D ). Of note, LKB1 is frequently mutated in NSCLC patients with mucinous bronchiolar adenocarcinoma (Osoegawa et al., 2011) .
Next, we characterized AMPK and mTORC1 signaling in K luc , KL luc , and KP luc lung tumors by immunohistochemical staining for P-AMPK and P-4E-BP1 ( Figure 2E ). Notably, the KL luc tumors contained the highest degree of P-4E-BP1, consistent with mTORC1 being particularly hyperactive in LKB1-deficient tumors. Lkb1 deletion in the Kras mutant tumors was also accompanied by near-complete loss of P-AMPK as seen in many other tissues previously ( Figure 2E ).
Phenformin Activates the AMPK Signaling Pathway in K luc and KP luc Lung Nodules To further examine their prospects as anticancer agents, we compared the bioavailability of metformin and phenformin in mouse lung tissue. Phenformin is a more lipophilic molecule compared to metformin ( Figure S3A ) and, unlike metformin requiring OCT1 for cell entry (Shu et al., 2007) , readily permeates cells and tissues (Hawley et al., 2010; Huang et al., 2008) . We performed intraperitoneal (i.p.) injections of vehicle, metformin, or phenformin on wild-type mice and isolated lung tissue at 1, 4, and 8 hr postinjection. Immunoblot analysis showed a weaker activation of the AMPK signaling pathway by metformin that only was observed at the 1 hr time point, unlike phenformin, which showed a robust activation at 4 hr postinjection ( Figure 3A ). However, mice bearing lung tumors did not tolerate daily i.p. injections over multiple weeks, and therefore phenformin was administered through the drinking water of mice fed ad libitum, as previously described (Appleyard et al., 2012; Huang et al., 2008) . Quantitative analysis of P-AMPK staining in KP luc lung tumors from mice treated for 2 weeks showed greater activation of AMPK with phenformin than metformin (Figures S3B and S3C). As expected, no induction of P-AMPK was ever seen in KL luc tumors. Measurement of metformin and phenformin in blood plasma of mice by mass spectrometry revealed that levels of both were steady over days when administered via drinking water ( Figure S3D ).
Immunoblot analysis of snap-frozen K luc , KL luc , and KP luc lung tumor nodules revealed that tumors from K luc and KP luc mice treated with phenformin had higher levels of AMPK activation compared to vehicle treated mice, whereas KL luc lung tumors showed a lack of AMPK signaling as expected ( Figure 3B (C) Representative images of K luc , KL luc , and KP luc lung tumor sections stained with hematoxylin and eosin (H&E), P-AMPK, or P-4E-BP1. P-AMPK or P-4E-BP1 positively stained cells (in green) and nuclei (in blue). Scale bar = 100 mm.
(D and E) Box plots representing the mean P-AMPK (D) or P-4E-BP1 (E) signal from K luc , KL luc , and KP luc lung tumors treated with vehicle or phenformin. n = 6 mice analyzed per treatment group in each genotype (K luc , KL luc , and KP luc ) treatment group. All data are represented as the mean ± SEM. See also Figure S3 .
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Phenformin Therapy Targets LKB1-Deficient NSCLC Normal lung lysates from wild-type FVB mice given phenformin ad libitum for 2 weeks showed an increase in AMPK signaling and lowered mTORC1 signaling, when compared to the vehicle treated mice ( Figure S3E ). Phenformin also increased levels of P-eIF2a and its target BiP/Grp78 in normal lung as well as in lung tumors ( Figures S3E and S3F ) (the CHOP antibody afore used recognized human but not mouse CHOP). There was no observed difference in IGF-IR/IR or Akt signaling between the vehicle-or phenformin-treated mice. Analysis of the AMPK activation in lung tumors by quantitative immunohistochemistry following phenformin treatment paralleled the results observed by immunoblotting ( Figures 3C and 3D) , and phenformin was observed to modestly reduce the mTORC1 substrate P-4E-BP1 levels in all genotypes ( Figures 3C and 3E ). Figures S4A-S4C ). We first tested phenformin as a chemotherapeutic by initiating treatment 6 weeks postadenoviral cre delivery for the KP luc and KL luc mice and 9 weeks postadenoviral cre delivery in the K luc mice ( Figure S4D ) in order to target aggressively growing tumors transitioning from benign to malignant tumors (Figures 2A-2C ). After 3 weeks of treatment, BLI imaging revealed modestly reduced tumor burden in mice of all genotypes receiving phenformin, but the only statistically significant decrease was in the KL luc lung tumors ( Figures 4A  and 4B ).
To better quantify tumor burden in mice, we combined BLI with quantitative histological analysis. H&E-stained lungs were imaged with morphometric software to quantify the surface area composed of tumor as opposed to normal tissue of representative cross-sections of each lung lobe for each mouse was determined ( Figures S4E and S4F) . Importantly, tumor burden determined by histological analysis correlated closely with BLI. KL luc mice showed significant reductions in lung tumor area ( Figures 4C and 4D) , while modest reductions in tumor burden were also seen in both K luc and KP luc mice. Normalization of the tumor burden for each tumor genotype, performed by calculating the ratio of phen:veh tumor mass, showed the largest decrease in tumor burden for the KL luc mice as compared to K luc and KP luc mice ( Figure S4G ). In addition, we observed no change in rate of metastasis following phenformin treatment in any of our therapeutic trials. These results demonstrate phenformin as a single agent selectively attenuates Lkb1-deficient lung tumor growth in vivo.
We next analyzed apoptosis and tumor proliferation in the lung tumors by TUNEL and Ki67 staining, respectively. Phenformin treatment modestly reduced Ki67 index in KL luc tumors but not K luc and KP luc tumors ( Figures 4E and 4F) , and TUNEL staining revealed that KL luc lung tumors had the highest levels of apoptotic tumor cells following phenformin (Figures 4E and   4G ). Interestingly, KL luc lung tumors also had higher basal levels of apoptosis compared to KP luc and K luc tumors, perhaps reflecting the prosurvival role of LKB1 in restoring energy homeostasis under conditions of metabolic stress, which may spontaneously arise in the context of a tumor.
Phenformin Induced a Significant Increase in Survival and Therapeutic Response in KL luc Mice following Long-Term Treatment Given the response of late-stage KL luc lung tumors to phenformin treatment, we decided to treat earlier stage lung tumors in KL luc and KP luc mice. To better mimic the human clinical use of biguanides, we used oral gavage (o.p.) to deliver daily the maximum tolerated dose of 100 mg/kg phenformin starting at 3 weeks posttumor induction ( Figure S5A ). As expected, delivery of phenformin by this method resulted in AMPK pathway activation in KP luc but not KL luc tumor nodules ( Figures S5B and S5C ). Mass spectrometry on phenformin in blood plasma following o.p. delivery demonstrated a rapid uptake of phenformin followed by a steady decrease in blood plasma over 24 hr (Figure S5D) . Importantly, these FVB mice are on a chow diet and nondiabetic, and the dose of phenformin used following 6 weeks of daily administration did not significantly impact blood plasma insulin levels, glucose levels, or lead to increased blood lactate levels as compared to vehicle-treated mice ( Figures S5E-S5H) .
The loss of LKB1 function in tumors predicts increased glycolytic metabolism and 18 F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) avidity as shown in gastrointestinal polyps from Lkb1 +/À mice ) and in NSCLC in mice and humans (Chen et al., 2012) . Therefore, we explored the use of FDG-PET as a surrogate endstage biomarker in combination with microCT (mCT) imaging to longitudinally monitor tumor progression and response in KL luc and KP luc mice following phenformin treatment. KL luc and KP luc mice were given baseline FDG-PET and mCT scans, which were scored by a radiologist blinded to the identities of the mice. Mice in both groups were determined to be negative for tumors by both PET and CT scans and were randomly sorted into treatment groups ( Figure 5C ). When phenformin was administered by o.p. for an extended time, it significantly increased survival in KL luc mice compared to KP luc mice ( Figures 5A and 5B ). Phenformin treatment resulted in delayed tumor progression in KL luc but not KP luc mice as shown by mCT measurements of lung tumor volume over time for individual mice in the study ( Figures 5C-5E , S5J, and S5K). At 4 and 6 weeks of treatment, average lung tumor size was significantly reduced in KL luc mice ( Figure 5D ). There was a trend toward smaller tumors in the KP luc mice but did not reach statistical significance ( Figure 5E ). However, at endstage, there was the presence of large, advanced solid tumors of the vehicle and phenformin groups in both KL luc and KP luc tumor genotypes ( Figure S5I ). The 18 FDG uptake into tumors was quantified by the standardized uptake value (SUVmax) at 4 and 6 weeks of treatment. The SUVmax for phenformin-treated KL luc lung tumors was significantly reduced compared to vehicle ones ( Figure 5F ). No difference was seen in the SUVmax for the KP luc mice at these same time points ( Figure 5G ). These data suggest a therapeutic response in KL luc lung tumors following phenformin treatment. However, the SUVmax values in endstage tumors were (legend continued on next page)
Phenformin Therapy Targets LKB1-Deficient NSCLC increased in both KL luc and KP luc mice ( Figures S5L and S5M ), suggesting the emergence of phenformin-resistant tumors in KL luc mice ( Figures S5J and S5L ). Histopathological analysis of 6 week o.p. phenformin-treated lungs revealed that KL luc but not KP luc lung tumors had large regions of necrosis, which was absent in the vehicle-treated controls ( Figure 6A ; Figure S6A ). Further analysis of KL luc lung sections revealed an 8-fold increase in necrotic tumor areas as shown by the presence of necrotic bodies with ghost cells (Figures 6B and 6F) . Staining of KL luc and KP luc tumors for cleaved caspase 3 revealed a significant increase in tumor cell apoptosis in both KL luc and KP luc lung tumors following phenformin ( Figures 6C, 6G , S6A, and S6B) but no difference in Ki67 indices in either genotype following phenformin treatment ( Figures 6D, 6H , S6A, and S6C). Elevated P-AMPK levels were observed in both tumor and lung parenchyma of phenformintreated KP luc mice ( Figure S6D ), further reflecting that this dosing regimen was capable of inducing energy stress in these different lung cell populations. Strikingly, the abundant mucinous bronchiolar-epithelial adenocarcinoma (mBEAC), which occluded much of the upper airways in KL luc mice, showed a 2-fold decrease in surface area in mice receiving phenformin compared to the vehicle group ( Figures 6E and 6I) . Altogether, these results indicate that phenformin as a single agent induces a tumor response in both KL luc and KP luc lung tumors with Lkb1-deficient tumors showing the most robust overall therapeutic response to phenformin.
Mitochondrial Defects May Sensitize LKB1-Deficient NSCLC Tumor Cells to Phenformin
To examine the molecular mechanism behind the selective induction of apoptosis in LKB1-deficient lung cancer cells, we analyzed signals downstream of its main target AMPK. Recently, we demonstrated that AMPK phosphorylates and activates the autophagy kinase ULK1, which is required for mitophagy and cell survival under starvation conditions (Egan et al., 2011) . We previously observed an accumulation of mitochondria with defective mitochondrial membrane potential (Dc) in Ampk-and Ulk1-KO fibroblasts and hepatocytes (Egan et al., 2011) , similar to that observed in Lkb1-KO hematopoetic stem cells (Nakada et al., 2010) , so we examined here whether ULK1 and mitochondrial homeostasis might be disrupted in LKB1 mutant NSCLC cells. A549 cells reconstituted with functional LKB1 showed AMPK activation and its phosphorylation of endogenous ULK1 on Ser555 following phenformin treatment, paralleling phosphorylation of Raptor, another AMPK substrate ( Figure 7A ). Phenformin treatment also resulted in a decrease in levels of the p62/ Sqstm1 protein only in the wild-type LKB1-reconstituted cells, indicative of efficient autophagy reliant on LKB1 function (Figure 7A) . Importantly, p62 levels were not reduced by metformin here, perhaps reflecting the lower level of AMPK signaling from metformin as compared to phenformin. Expression of functional LKB1 in LKB1-deficient H157 and H838 cells also restored their P-Ser555 ULK1 signal, indicating this is a general defect in LKB1-deficient NSCLC cell lines ( Figure S7A ). As observed previously in AMPK-and ULK1-defective fibroblasts and hepatocytes, here A549, H157, and H838 NSCLC cells defective for LKB1 function exhibited increased mitochondrial content as assayed by flow cytometry for mitotracker red staining ( Figure 7B and S7B), suggesting that reconstitution of wild-type LKB1 into these LKB1-deficient NSCLC cell lines may actively induce functional mitophagy. A549-pBabe and A549-LKB1 KD cells had impaired Dc, reflecting impaired mitochondrial membrane integrity, as exhibited by the failure of JC-1 dye to accumulate in the mitochondrial membrane when compared to A549-LKB1
WT cells (red to green ratio of JC-1 staining in Figure 7C ). Following treatment with phenformin, LKB1-deficient tumor cells showed a complete loss of mitochondrial membrane potential, whereas expression of functional LKB1 fully prevented this loss. In contrast, treatment with the mitochondrial uncoupler CCCP induced loss of Dc in all cell lines, though LKB1-reconstituted cells still retained the most mitochondrial membrane potential ( Figure 7C ). As one measure of functionality of the mitochondria in these cell lines, we examined oxygen consumption as a direct measurement of mitochondrial respiration. Consistent with mitochondrial defects, A549-pBabe and A549-LKB1 KD cells had a lower basal rate of oxygen consumption rate (OCR) than the A549 WT cells (Figures 7D and S7C) . Treatment of these cells with either phenformin or rotenone resulted in inhibition of mitochondrial respiration as shown by an acute drop OCR in levels ( Figures S7C and S7D) . OCR levels tracked inversely with mitotracker red staining here, consistent with the idea that the accumulated mitochondria in the LKB1-deficient cells are respiration defective.
Mitochondrial Complex I inhibition has been reported to induce reactive oxygen species (ROS) similar to that seen with Complex III inhibition (Hirst et al., 2008; Kushnareva et al., 2002) . Thus, we next examined the release of mitochondrial reactive oxygen species (mtROS) following the treatment with phenformin, metformin, or the complex III inhibitor antimycin A and found that phenformin was a more potent inducer of mtROS than metformin ( Figure S7E ). Staining of A549-pBabe and A549-LKB1 KD cells showed modest elevations in mtROS compared to A549-LKB1 WT cells, both basally and following phenformin treatment ( Figure 7E ). To examine whether the doses of phenformin used in our therapeutic study were effective enough to induce LKB1-dependent effects on mitophagy, we performed western blot analysis of lung tumor nodules from mice with and without phenformin treatment for 5 days and discovered reduced phosphorylation of ULK1 and an accumulation of the mitophagy regulator Parkin in KL luc but not K luc , or KP luc lung tumors ( Figure 7F ). These results suggest defects of the AMPK-ULK1 signaling 
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Phenformin Therapy Targets LKB1-Deficient NSCLC pathway and mitophagy in vivo following loss of LKB1 (Figure 7G) , which may help sensitize these tumors to the effects of phenformin on mitochondrial integrity.
DISCUSSION
In this study we have found that the diabetes drug phenformin shows selective and significant antitumor activity in genetically engineered mouse models of lung cancer bearing LKB1 mutations. Molecular targeted therapeutics hold great promise for the future of cancer treatment, but for the 15%-30% of NSCLC bearing inactivating mutations in LKB1, there has been little in the way of targeted agents to date. As loss of LKB1 results in hyperactivation of mTORC1 in addition to other progrowth pathways (Shackelford and Shaw, 2009), initial interest has been in rapamycin analogs or other mTOR inhibitors. However, rapamycin treatment of an autochthonous lung tumor model with Kras and Lkb1 mutations similar to the one used here showed a minimal therapeutic effect (Liang et al., 2010) , perhaps because of the multitude of pathways deregulated from LKB1 deficiency that can still fuel tumorigenesis even when mTORC1 is suppressed. Hyperactivation of Src family kinases was also discovered as a biochemical marker and potential therapeutic target in Lkb1-deficient lung tumors (Carretero et al., 2010) . Combination of the Src inhibitor dasatinib with PI3K and MEK inhibitors in similar mouse lung tumor models showed a synergistic tumor response, though dasatinib as a single agent displayed a minimal effect (Carretero et al., 2010) . The fact that phenformin induces therapeutic response as a single agent taken together with the success of dasatinib in combinations suggests that phenformin may also show greater success in defined combinations, which will be a focus for future investigations. Of relevance, a recent study treating the same three NSCLC models used here with a combination of standard-of-care docetaxel with MEK inhibitors revealed that Kras; Lkb1 mutant tumors were selectively resistant to that combination, unlike Kras alone or Kras; p53 mutant tumors (Chen et al., 2012) . It is in the context of this body of work that selective sensitivity of Kras; Lkb1 tumors to phenformin as a single agent in aggressive autochthonous models of lung cancer is so notable.
We have been interested in whether one could utilize metabolic stress-inducing compounds as anticancer agents for LKB1 mutant tumors in their autochthonous setting in the intact organism ever since we observed that LKB1-deficient cells were sensitive to apoptosis induced by metabolic stress in culture (Shaw et al., 2004) . We focused our attention on the biguanide family of antidiabetes therapeutics for their ability to reduce intracellular ATP levels as a result of mitochondrial complex I inhibition. The absence of LKB1 signaling to AMPK means such cells will go for an extended time without activation of this sensor to restore ATP levels. We expect that mitochondrial damage and ATP loss also activate AMPK-independent stress sensing pathways, as we demonstrate here with multiple markers of the eIF2a signaling pathway. These findings are consistent with previous reports of AMPK-independent effects of biguanides (Foretz et al., 2010; Kalender et al., 2010) . Our results are also consistent with recent studies demonstrating that AMPK mediates cell survival following metabolic stress not only through effects on ATP restoration but also by restoring NADPH levels, which are needed to neutralize ROS that arise during these stresses (Jeon et al., 2012) . Inhibition of mitochondria complex I has been shown to cause ROS induction (Hirst et al., 2008; Kushnareva et al., 2002) , so the fact that phenformin is a potent complex I inhibitor may underlie its ROS generation, which LKB1-deficient cells are genetically incapable of neutralizing efficiently. Future studies will be needed to fully assess the contribution of ROS in the LKB1-sensitive apoptosis following phenformin.
The biguanide metformin is the most widely used type 2 diabetes therapeutic worldwide and more recently has become used in treating other insulin-resistant conditions, including polycystic ovary syndrome (PCOS) (Motta, 2008) . Metformin garnered considerable attention as a potential anticancer agent once the connection between LKB1 and AMPK was discovered (Birsoy et al., 2012; Taubes, 2012) . As AMPK activation can be growth suppressive, diabetics taking these agents daily for decades might have a lowered incidence of cancer because of chronic effects from AMPK-mediated suppression of mTORC1 and other progrowth pathways, depending on how effective and sustained the clinical doses of metformin are at activating AMPK in different tissues. In addition, a non-cell-autonomous mechanism for metformin's antitumor effects may be its ability to lower circulating blood glucose and insulin levels, which also contribute to cancer risk and incidence in some contexts (Pollak, 2010) . A number of epidemiological studies have found that diabetics taking metformin exhibit lowered risk of overall cancer compared to those taking other forms of diabetes medication (Dowling et al., 2012; Pollak, 2012) . Given these observations, over 50 different clinical trials investigating the use of metformin in oncology are currently underway (http://www. clinicaltrials.gov). Whether phenformin would yield similar broad anticancer results, given that it also effectively lowers blood glucose and also more potently activates AMPK across a wide-variety of tissues, remains to be investigated. As phenformin has a 50-fold greater potency than metformin for mitochondrial complex I inhibition (Owen et al., 2000; Dykens et al., 2008) , part of its therapeutic success in cancer models when compared to metformin may be due to the fact that at maximal tolerated doses in rodents and clinically utilized doses in humans, one achieves greater ATP loss and ROS induction with phenformin. However, another distinction between these two biguanides is a greater tissue bioavailability for phenformin, which may be due to the apparent reliance of metformin on a tissue-restricted cell-surface transporter, Oct1, to efficiently cross the plasma membrane, unlike the more lipophilic phenformin (Hawley et al., 2010) . Phenformin was removed from clinical use for type 2 diabetes because of incidence of fatalities from lactic acidosis (Crofford, 1995; Owen et al., 2000) , reported in 64 cases per 100,000 patients per year, with patients bearing compromised kidney function at greatest risk. However, phenformin or another biguanide analog may still find utility as anticancer agents as the dosing and shorter duration in cancer therapy would be quite different from its prior clinical use for diabetes. Patients could also be prescreened for kidney function and other biomarkers to reduce any risk of lactic acidosis. Based on our findings here and previous studies of metformin, it seems most likely that phenformin might have potential use for early-stage lung tumors or as an adjuvant therapy following resection of early-stage NSCLC tumors. Although phenformin is unlikely to be suitable as a single-agent therapy in advanced-stage disease, it may synergize with other modalities, which warrants future investigation. A critical need for future clinical studies will be developing biomarkers of metformin and phenformin action in human tissues using clinically achievable doses (Pollak, 2010) . Our identification of phospho-Ser51 eIF2a and its targets CHOP and BiP/Grp78 as AMPK-independent markers of phenformin-induced stress may prove valuable for such studies.
Whether LKB1 deficiency confers sensitivity toward other agents that perturb ATP production via effects on mitochondria, glycolysis, or glutaminolysis also remains an interesting area for future targeted therapeutic development. Given the large percentage of sporadic lung, cervical, and endometrial cancers bearing LKB1 mutations, identifying agents selectively targeting LKB1 mutant tumors is a critical goal and one that seems particularly amenable to drugs targeting tumor metabolism.
EXPERIMENTAL PROCEDURES Antibodies and Reagents
Antibodies from Cell Signaling Technologies (Danvers, MA, USA) used for immunoblots were diluted 1:1,000 and included LKB1 (D60C5) (#3047), phospho-AMPK Thr172 (#2531), total AMPK a1/2 (#2532), phospho-Raptor Ser792 (#2083), total Raptor (#2280), phospho-ULK1 (ser555) (#5869), eIF4E (#9742), phospho-eIF2a (ser51) (#3398), total eIF2a (#9722), cleaved caspase 3 (#9664), PARP (#9542), cleaved PARP (Asp214) (#5625), cleaved PARP mouse-specific (Asp214) (#9544), phospho-S6 (ser255/236) (#4858), S6 (#2217), phospho-4E-BP1 (thr37/46) (#2855), 4E-BP1 (#9644), phospho-IGF-IR/IR (#3024), IGF-IR/IR (#3027), phospho-AKT (ser473) (#4060), AKT (#9272), CHOP (#5554), and BiP/GRP78 (#3177). Total ULK1 (A7481 WB 1:1,000) and anti-actin (A5441 WB1:5000) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The p53 (CM5) antibody was obtained from Vector Labs (Burlingame, CA, USA; VP-P956 WB 1:1,000). The p62 antibody was obtained from Progen (Heidelberg, Germany; #GP62-C). AICAR was obtained from Toronto Research Chemicals (North York, Ontario, Canada). Phenformin, Metformin, and 2-deoxyglucose (2DG) and Antimycin A (cat. no. A8674); were purchased from Sigma-Aldrich. CCCP was obtained from the Molecular Probes JC-1 dye kit (Carlsbad, CA, USA; cat no. M34152).
Cell Culture
Cells were incubated at 37 C and maintained at 5% CO2. A549, H460, A427, H838, and HeLa cell lines were obtained from ATCC, and H157 cells were a kind gift from Dr. John Minna. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) or RPMI 1640 medium (GIBCO) plus 10% fetal bovine serum (Hyclone, Logan, UT, USA) and penicillin and streptomycin. Retroviral gene expression was performed as described previously (Gwinn et al., 2008) . Briefly, for retroviral infection, the pBabe, pBabe-FLAG-LKB1, and pBabe-FLAG-LKB1-KD (Addgene #'s 1764, 8592, and 8593) constructs were transfected along with the ampho packaging plasmid into growing HEK293T cells. Viral supernatants were collected 48 hr after transfection, spun for 5 min at 3,000 rpm, and filtered, and target cells were infected in the presence of polybrene. Twenty-four hours later, cells were selected with puromycin. Cells were plated at a density of 1 3 10 5 per well in 6-well dishes and grown for 18 hr before treatment.
Mouse Therapeutic Trials
Lox-Stop-Lox Kras G12D were obtained from Tyler Jacks at Massachusetts
Institute of Technology (Jackson et al., 2005) and p53 lox/lox mice from the Mouse Models of Human Cancers Consortium (Jonkers et al., 2001) . Lkb1 lox/lox mice are as previously reported (Shaw et al., 2005) . Rosa26-LoxStop-Lox-Luc mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) courtesy of Bill Kaelin (Safran et al., 2003) . Mice were inbred on an FVB background. Lung tumors were induced by intranasal inhalation of 5 3 10 6 plaque forming units adeno-Cre (purchased from University of Iowa adenoviral core) as previously described (Jackson et al., 2005) . Mice that displayed with clinical signs of disease, such as labored breathing or severe weight loss, were euthanized and necropsied. The mean tumor latencies we observed were comparable to previous studies with the exception of KP luc mice, which developed large, aggressive lung tumors with the same latency of KL luc mice (Jackson et al., 2005; Ji et al., 2007) . In the experiments in Figure 4, mice were administered with vehicle (water), metformin, or phenformin (Toronto Research Corporation, Ontario, Canada) ad lib through their drinking water, and their daily intake of fluids were monitored. Fresh metformin (1.8 mg/ml) or phenformin (1.8 mg/ml) was administered every other day. Long-term treatments consisted of 3 weeks treatment (schematic in Figure S4D) , and acute treatments lasted 5 days. For the intraperitoneal injections in Figure 4A , mice were given one injection of saline (0.9%), metformin (300 mg/kg), or phenformin (150 mg/kg) and euthanized at 1, 4, and 8 hr postinjection, and lung tissue was isolated. In the therapeutic trials in Figures 5 and 6 (schematized in Figure S5A ), mice were administered phenformin (100 mg/kg/day) by o.p. once daily 6 days/week beginning at 3 weeks postdelivery of adenovirus expressing Cre. All experimental procedures performed on mice were approved by the Salk Institute and University of California at Los Angeles Institutional Animal Care and Use Committees.
Statistical Analysis Methods
Means were compared and p values determined by parametric or nonparametric ANOVA, and statistical test details and significance at p < 0.05 are indicated in the text and figure legends. Survival curves were computed using the Kaplan-Meier method. All statistical calculations were carried out using GraphPad Prism 5 software (San Diego, CA) or SAS 9.3 (SAS, Cary, NC). For analysis of SUVmax and tumor volume from FDG-PET and mCT imaging, comparisons were made between vehicle (V) versus Phenformin (P) treatments at week 7 and week 9. Values that were below the level of detection, referred to as left-censored observations, were coded with ''zero'', although the actual value may be above zero but is usually lower than the lowest observed value.
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